Endocrinology and Metabolism

The Korean Endocrine Society (대한내분비학회)
권호 표지
DOI QR코드

DOI QR Code

Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies

  • Moon, Shinje (Division of Endocrinology and Metabolism, Hallym University College of Medicine) ;
  • Chung, Hye Soo (Division of Endocrinology and Metabolism, Hallym University College of Medicine) ;
  • Yu, Jae Myung (Division of Endocrinology and Metabolism, Hallym University College of Medicine) ;
  • Yoo, Hyung Joon (Department of Internal Medicine, CM Hospital) ;
  • Park, Jung Hwan (Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Kim, Dong Sun (Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Park, Young Joo (Department of Internal Medicine, Seoul National University College of Medicine)
  • Received : 2018.09.04
  • Accepted : 2018.10.05
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Background: Epidemiological studies have suggested an association between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) development. Other studies, however, have reported a protective role of HT against PTC progression. Through this updated meta-analysis, we aimed to clarify the effects of HT on the progression of PTC. Methods: We searched citation databases, including PubMed and Embase, for relevant studies from inception to September 2017. From these studies, we calculated the pooled odds ratios (ORs) of clinicopathologic features and the relative risk (RR) of PTC recurrence with 95% confidence intervals (CIs) using the Mantel-Haenszel method. Additionally, the Higgins $I^2$ statistic was used to test for heterogeneity. Results: The meta-analysis included 71 published studies with 44,034 participants, among whom 11,132 had HT. We observed negative associations between PTC with comorbid HT and extrathyroidal extension (OR, 0.74; 95% CI, 0.68 to 0.81), lymph node metastasis (OR, 0.82; 95% CI, 0.72 to 0.94), distant metastasis (OR, 0.49; 95% CI, 0.32 to 0.76), and recurrence (RR, 0.50; 95% CI, 0.41 to 0.61). Conclusion: In this meta-analysis, PTC patients with HT appeared to exhibit more favorable clinicopathologic characteristics and a better prognosis than those without HT.

Keywords

References

  1. Ahmed R, Al-Shaikh S, Akhtar M. Hashimoto thyroiditis: a century later. Adv Anat Pathol 2012;19:181-6. https://doi.org/10.1097/PAP.0b013e3182534868
  2. Latina A, Gullo D, Trimarchi F, Benvenga S. Hashimoto's thyroiditis: similar and dissimilar characteristics in neighboring areas: possible implications for the epidemiology of thyroid cancer. PLoS One 2013;8:e55450. https://doi.org/10.1371/journal.pone.0055450
  3. Ehlers M, Schott M. Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metab 2014;25:656-64. https://doi.org/10.1016/j.tem.2014.09.001
  4. Choi YM, Kim TY, Jang EK, Kwon H, Jeon MJ, Kim WG, et al. Standardized thyroid cancer mortality in Korea between 1985 and 2010. Endocrinol Metab (Seoul) 2014;29:530-5. https://doi.org/10.3803/EnM.2014.29.4.530
  5. Lee JH, Kim Y, Choi JW, Kim YS. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis. Eur J Endocrinol 2013;168:343-9. https://doi.org/10.1530/EJE-12-0903
  6. Lai X, Xia Y, Zhang B, Li J, Jiang Y. A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk. Oncotarget 2017;8:62414-24.
  7. Huang BY, Hseuh C, Chao TC, Lin KJ, Lin JD. Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol 2011;22:144-9. https://doi.org/10.1007/s12022-011-9164-9
  8. Kim EY, Kim WG, Kim WB, Kim TY, Kim JM, Ryu JS, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2009;71:581-6. https://doi.org/10.1111/j.1365-2265.2009.03537.x
  9. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 1995;80:3421-4.
  10. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5. https://doi.org/10.1007/s10654-010-9491-z
  11. Song E, Jeon MJ, Park S, Kim M, Oh HS, Song DE, et al. Influence of coexistent Hashimoto's thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2018;88:123-8. https://doi.org/10.1111/cen.13475
  12. Cortes MCS, Rosario PW, Mourao GF, Calsolari MR. Influence of chronic lymphocytic thyroiditis on the risk of persistent and recurrent disease in patients with papillary thyroid carcinoma and elevated antithyroglobulin antibodies after initial therapy. Braz J Otorhinolaryngol 2018;84:448-52. https://doi.org/10.1016/j.bjorl.2017.05.005
  13. Zhang Q, Liu BJ, Ren WW, He YP, Li XL, Zhao CK, et al. Association between BRAF V600E mutation and ultrasound features in papillary thyroid carcinoma patients with and without Hashimoto's thyroiditis. Sci Rep 2017;7:4899. https://doi.org/10.1038/s41598-017-05153-y
  14. Sun Y, Liu X, Ouyang W, Feng H, Wu J, Chen P, et al. Lymph node characteristics for predicting locoregional recurrence of papillary thyroid cancer in adolescents and young adults. Oral Oncol 2017;66:22-7. https://doi.org/10.1016/j.oraloncology.2016.12.028
  15. Marotta V, Sciammarella C, Chiofalo MG, Gambardella C, Bellevicine C, Grasso M, et al. Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer 2017;24:485-93. https://doi.org/10.1530/ERC-17-0085
  16. Carvalho MS, Rosario PW, Mourao GF, Calsolari MR. Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy. Endocrine 2017;55:954-8. https://doi.org/10.1007/s12020-016-1185-1
  17. Zhu Y, Zheng K, Zhang H, Chen L, Xue J, Ding M, et al. The clinicopathologic differences of central lymph node metastasis in predicting lateral lymph node metastasis and prognosis in papillary thyroid cancer associated with or without Hashimoto's thyroiditis. Tumour Biol 2016;37:8037-45. https://doi.org/10.1007/s13277-015-4706-2
  18. Zhu F, Shen YB, Li FQ, Fang Y, Hu L, Wu YJ. The effects of Hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma: a retrospective Chinese Cohort Study. Medicine (Baltimore) 2016;95:e2674. https://doi.org/10.1097/MD.0000000000002674
  19. Zeng RC, Jin LP, Chen ED, Dong SY, Cai YF, Huang GL, et al. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer. Head Neck 2016;38 Suppl 1:E1019-25. https://doi.org/10.1002/hed.24149
  20. Zeng R, Shou T, Yang KX, Shen T, Zhang JP, Zuo RX, et al. Papillary thyroid carcinoma risk factors in the Yunnan plateau of southwestern China. Ther Clin Risk Manag 2016;12:1065-74. https://doi.org/10.2147/TCRM.S105023
  21. Yu Y, Zhang J, Lu G, Li T, Zhang Y, Yu N, et al. Clinical relationship between IgG4-positive Hashimoto's thyroiditis and papillary thyroid carcinoma. J Clin Endocrinol Metab 2016;101:1516-24. https://doi.org/10.1210/jc.2015-3783
  22. Su X, He C, Ma J, Tang T, Zhang X, Ye Z, et al. RET/PTC rearrangements are associated with elevated postoperative TSH levels and multifocal lesions in papillary thyroid cancer without concomitant thyroid benign disease. PLoS One 2016;11:e0165596. https://doi.org/10.1371/journal.pone.0165596
  23. Nam HY, Lee HY, Park GC. Impact of co-existent thyroiditis on clinical outcome in papillary thyroid carcinoma with high preoperative serum antithyroglobulin antibody: a retrospective cohort study. Clin Otolaryngol 2016;41:358-64. https://doi.org/10.1111/coa.12520
  24. Siddiqui S, White MG, Antic T, Grogan RH, Angelos P, Kaplan EL, et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid 2016;26:807-15. https://doi.org/10.1089/thy.2015.0429
  25. Lin X, Chen X, Jiru Y, Du J, Zhao G, Wu Z. Evaluating the influence of prophylactic central neck dissection on TNM staging and the recurrence risk stratification of cN0 differentiated thyroid carcinoma. Bull Cancer 2016;103:535-40. https://doi.org/10.1016/j.bulcan.2016.04.003
  26. Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, et al. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma. Endocr Relat Cancer 2016;23:27-34. https://doi.org/10.1530/ERC-16-0335
  27. Kim SJ, Myong JP, Jee HG, Chai YJ, Choi JY, Min HS, et al. Combined effect of Hashimoto's thyroiditis and BRAF (V600E) mutation status on aggressiveness in papillary thyroid cancer. Head Neck 2016;38:95-101. https://doi.org/10.1002/hed.23854
  28. Dobrinja C, Makovac P, Pastoricchio M, Cipolat Mis T, Bernardi S, Fabris B, et al. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome. Int J Surg 2016;28 Suppl 1:S70-4. https://doi.org/10.1016/j.ijsu.2015.12.059
  29. Iliadou PK, Effraimidis G, Konstantinos M, Grigorios P, Mitsakis P, Patakiouta F, et al. Chronic lymphocytic thyroiditis is associated with invasive characteristics of differentiated thyroid carcinoma in children and adolescents. Eur J Endocrinol 2015;173:827-33. https://doi.org/10.1530/EJE-14-1046
  30. Zhu J, Wang X, Zhang X, Li P, Hou H. Clinicopathological features of recurrent papillary thyroid cancer. Diagn Pathol 2015;10:96. https://doi.org/10.1186/s13000-015-0346-5
  31. Wu Q, Li Y, Wang Y, Hu B. Sonographic features of primary tumor as independent predictive factors for lymph node metastasis in papillary thyroid carcinoma. Clin Transl Oncol 2015;17:830-4. https://doi.org/10.1007/s12094-015-1313-z
  32. Park JY, Kim DW, Park HK, Ha TK, Jung SJ, Kim DH, et al. Comparison of T stage, N stage, multifocality, and bilaterality in papillary thyroid carcinoma patients according to the presence of coexisting lymphocytic thyroiditis. Endocr Res 2015;40:151-5. https://doi.org/10.3109/07435800.2014.977911
  33. Kwak HY, Chae BJ, Eom YH, Hong YR, Seo JB, Lee SH, et al. Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis? Int J Clin Oncol 2015;20:463-73. https://doi.org/10.1007/s10147-014-0754-7
  34. Jiwang L, Zhendong L, Shuchun L, Bo H, Yanguo L. Clinicopathologic characteristics of familial versus sporadic papillary thyroid carcinoma. Acta Otorhinolaryngol Ital 2015;35:234-42.
  35. Girardi FM, Barra MB, Zettler CG. Papillary thyroid carcinoma: does the association with Hashimoto's thyroiditis affect the clinicopathological characteristics of the disease? Braz J Otorhinolaryngol 2015;81:283-7. https://doi.org/10.1016/j.bjorl.2014.04.006
  36. Cai YF, Wang QX, Ni CJ, Guo GL, Li Q, Wang OC, et al. The clinical relevance of Psammoma body and Hashimoto thyroiditis in papillary thyroid carcinoma: a large case-control study. Medicine (Baltimore) 2015;94:e1881. https://doi.org/10.1097/MD.0000000000001881
  37. Zhang Y, Ma XP, Deng FS, Liu ZR, Wei HQ, Wang XH, et al. The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer. World J Surg Oncol 2014;12:277. https://doi.org/10.1186/1477-7819-12-277
  38. Zhang Y, Dai J, Wu T, Yang N, Yin Z. The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 2014;140:1021-6. https://doi.org/10.1007/s00432-014-1629-z
  39. Yang Y, Chen C, Chen Z, Jiang J, Chen Y, Jin L, et al. Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2014;81:282-8. https://doi.org/10.1111/cen.12417
  40. Lang BH, Chai YJ, Cowling BJ, Min HS, Lee KE, Youn YK. Is BRAFV600E mutation a marker for central nodal metastasis in small papillary thyroid carcinoma? Endocr Relat Cancer 2014;21:285-95. https://doi.org/10.1530/ERC-13-0291
  41. Ryu IS, Song CI, Choi SH, Roh JL, Nam SY, Kim SY. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol 2014;21:277-83. https://doi.org/10.1245/s10434-013-3258-1
  42. Liu X, Zhu L, Cui D, Wang Z, Chen H, Duan Y, et al. Coexistence of histologically confirmed Hashimoto's thyroiditis with different stages of papillary thyroid carcinoma in a consecutive chinese cohort. Int J Endocrinol 2014;2014:769294.
  43. Liang K, He L, Dong W, Zhang H. Risk factors of central lymph node metastasis in cN0 papillary thyroid carcinoma: a study of 529 patients. Med Sci Monit 2014;20:807-11. https://doi.org/10.12659/MSM.890182
  44. Konturek A, Barczynski M, Nowak W, Wierzchowski W. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto's thyroiditis. Langenbecks Arch Surg 2014;399:229-36. https://doi.org/10.1007/s00423-013-1158-2
  45. Kim HG, Kim EK, Han KH, Kim H, Kwak JY. Pathologic spectrum of lymphocytic infiltration and recurrence of papillary thyroid carcinoma. Yonsei Med J 2014;55:879-85. https://doi.org/10.3349/ymj.2014.55.4.879
  46. Bircan HY, Koc B, Akarsu C, Demiralay E, Demirag A, Adas M, et al. Is Hashimoto's thyroiditis a prognostic factor for thyroid papillary microcarcinoma? Eur Rev Med Pharmacol Sci 2014;18:1910-5.
  47. Giagourta I, Evangelopoulou C, Papaioannou G, Kassi G, Zapanti E, Prokopiou M, et al. Autoimmune thyroiditis in benign and malignant thyroid nodules: 16-year results. Head Neck 2014;36:531-5. https://doi.org/10.1002/hed.23331
  48. Ye ZQ, Gu DN, Hu HY, Zhou YL, Hu XQ, Zhang XH. Hashimoto's thyroiditis, microcalcification and raised thyrotropin levels within normal range are associated with thyroid cancer. World J Surg Oncol 2013;11:56. https://doi.org/10.1186/1477-7819-11-56
  49. Shin JH, Ha TK, Park HK, Ahn MS, Kim KH, Bae KB, et al. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma. Int J Surg 2013;11:944-7. https://doi.org/10.1016/j.ijsu.2013.06.015
  50. Marotta V, Guerra A, Zatelli MC, Uberti ED, Di Stasi V, Faggiano A, et al. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. Clin Endocrinol (Oxf) 2013;79:733-8.
  51. Kim YS, Choi HJ, Kim ES. Papillary thyroid carcinoma with thyroiditis: lymph node metastasis, complications. J Korean Surg Soc 2013;85:20-4. https://doi.org/10.4174/jkss.2013.85.1.20
  52. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid 2013;23:1423-30. https://doi.org/10.1089/thy.2013.0036
  53. Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z, et al. Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg 2013;148:396-402. https://doi.org/10.1177/0194599812472426
  54. Jara SM, Carson KA, Pai SI, Agrawal N, Richmon JD, Prescott JD, et al. The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma. Surgery 2013;154:1272-80. https://doi.org/10.1016/j.surg.2013.07.021
  55. Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metab 2013;98:2409-14. https://doi.org/10.1210/jc.2013-1309
  56. Cordioli MI, Cury AN, Nascimento AO, Oliveira AK, Mello M, Saieg MA. Study of the histological profile of papillary thyroid carcinomas associated with Hashimoto's thyroiditis. Arq Bras Endocrinol Metabol 2013;57:445-9. https://doi.org/10.1590/S0004-27302013000600006
  57. Yoon YH, Kim HJ, Lee JW, Kim JM, Koo BS. The clinicopathologic differences in papillary thyroid carcinoma with or without co-existing chronic lymphocytic thyroiditis. Eur Arch Otorhinolaryngol 2012;269:1013-7. https://doi.org/10.1007/s00405-011-1732-6
  58. Paulson LM, Shindo ML, Schuff KG. Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2012;147:444-9. https://doi.org/10.1177/0194599812445727
  59. Jeong JS, Kim HK, Lee CR, Park S, Park JH, Kang SW, et al. Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome. J Korean Med Sci 2012;27:883-9. https://doi.org/10.3346/jkms.2012.27.8.883
  60. Campos LA, Picado SM, Guimaraes AV, Ribeiro DA, Dedivitis RA. Thyroid papillary carcinoma associated to Hashimoto's thyroiditis. Braz J Otorhinolaryngol 2012;78:77-80. https://doi.org/10.5935/1808-8694.20120037
  61. Villagelin DG, Santos RB, Romaldini JH. Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis? J Endocrinol Invest 2011;34:e403-8.
  62. Nemetz MA, Thomazelli FC, Granero LC, Nemetz AB, Dos Santos MB. Does chronic lymphocytic thyroiditis influence the staging of differentiated thyroid carcinoma?. Braz J Otorhinolaryngol 2011;77:77-83. https://doi.org/10.1590/S1808-86942011000100013
  63. Kim SS, Lee BJ, Lee JC, Kim SJ, Jeon YK, Kim MR, et al. Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck 2011;33:1272-7. https://doi.org/10.1002/hed.21594
  64. Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 2011;18:429-37. https://doi.org/10.1530/ERC-11-0028
  65. Ahn D, Heo SJ, Park JH, Kim JH, Sohn JH, Park JY, et al. Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol 2011;50:1228-34. https://doi.org/10.3109/0284186X.2011.602109
  66. Kim KW, Park YJ, Kim EH, Park SY, Park DJ, Ahn SH, et al. Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck 2011;33:691-5. https://doi.org/10.1002/hed.21518
  67. Mazokopakis EE, Tzortzinis AA, Dalieraki-Ott EI, Tsartsalis AN, Syros PK, Karefilakis CM, et al. Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma: a retrospective study. Hormones (Athens) 2010;9:312-7. https://doi.org/10.14310/horm.2002.1282
  68. Consorti F, Loponte M, Milazzo F, Potasso L, Antonaci A. Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto's thyroiditis. Eur Surg Res 2010;45:333-7. https://doi.org/10.1159/000320954
  69. Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 2010;72:702-8. https://doi.org/10.1111/j.1365-2265.2009.03699.x
  70. Kim HS, Choi YJ, Yun JS. Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis. Endocr Pathol 2010;21:149-53. https://doi.org/10.1007/s12022-010-9124-9
  71. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 2010;95:2325-33. https://doi.org/10.1210/jc.2009-2564
  72. Gul K, Dirikoc A, Kiyak G, Ersoy PE, Ugras NS, Ersoy R, et al. The association between thyroid carcinoma and Hashimoto's thyroiditis: the ultrasonographic and histopathologic characteristics of malignant nodules. Thyroid 2010;20:873-8. https://doi.org/10.1089/thy.2009.0118
  73. Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 2009;19:137-41. https://doi.org/10.1089/thy.2008.0144
  74. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 2007;204:764-73. https://doi.org/10.1016/j.jamcollsurg.2006.12.037
  75. Kurukahvecioglu O, Taneri F, Yuksel O, Aydin A, Tezel E, Onuk E. Total thyroidectomy for the treatment of Hashimoto's thyroiditis coexisting with papillary thyroid carcinoma. Adv Ther 2007;24:510-6. https://doi.org/10.1007/BF02848773
  76. Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001;25:632-7. https://doi.org/10.1007/s002680020165
  77. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 1999;126:1070-6. https://doi.org/10.1067/msy.2099.101431
  78. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998;8:197-202. https://doi.org/10.1089/thy.1998.8.197
  79. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955;70:291-7. https://doi.org/10.1001/archsurg.1955.01270080137023
  80. Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 2013;98:474-82. https://doi.org/10.1210/jc.2012-2978
  81. Liotti F, Visciano C, Melillo RM. Inflammation in thyroid oncogenesis. Am J Cancer Res 2012;2:286-97.
  82. Latrofa F, Ricci D, Grasso L, Vitti P, Masserini L, Basolo F, et al. Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies. J Clin Endocrinol Metab 2008;93:591-6. https://doi.org/10.1210/jc.2007-1199
  83. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 1999;84:458-63. https://doi.org/10.1210/jcem.84.2.5443
  84. Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerstrom G, Rastad J, et al. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 1996;27:1329-35. https://doi.org/10.1016/S0046-8177(96)90346-9
  85. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997;275:960-3. https://doi.org/10.1126/science.275.5302.960
  86. Zhang Q, Liu SZ, Zhang Q, Guan YX, Chen QJ, Zhu QY. Meta-analyses of association between BRAF(V600E) mutation and clinicopathological features of papillary thyroid carcinoma. Cell Physiol Biochem 2016;38:763-76. https://doi.org/10.1159/000443032